Brief: XBiotech Developing Novel True Human Antibody Targeting Interleukin-1Alpha
April 14 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH DEVELOPING NOVEL TRUE HUMAN ANTIBODY TARGETING
INTERLEUKIN-1ALPHA (IL-1⍺)
* XBIOTECH INC - ON SCHEDULE TO REENTER CLINIC WITH A NEW
ANTI-IL-1⍺ THERAPY IN 2021
Source text for Eikon: ID:nGNX3dnfJb
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke